Table 3 Relationship between awareness of the benefit of genome study and awareness of the Nagahama study, self-rated understanding of terminology, concern, and belief of usage of genetic information in companies or government bodies from Logistic Regression Analysis

High awareness of the Nagahama study

191 (34.8)

14 (12.4)

3.82

1.93–7.57

<0.001

326 (55.6)

40 (33.3)

2.63

1.63–4.24

<0.001

 High

231 (41.8)

19 (16.5)

1

168 (28.8)

15 (12.6)

1

 Middle

206 (37.3)

30 (26.1)

0.66

0.34–1.29

0.223

224 (38.4)

37 (31.1)

0.72

0.36–1.42

0.342

 Low

116 (21.0)

66 (57.4)

0.24

0.12–0.46

<0.001

192 (32.9)

67 (56.3)

0.49

0.27–0.98

0.045

 Financial infusion

456 (84.0)

60 (52.2)

4.37

2.49–7.69

<0.001

473 (81.4)

65 (53.7)

2.98

1.79–4.97

<0.001

 Privacy concerns

343 (62.5)

56 (49.6)

0.72

0.39–1.32

0.284

335 (56.9)

53 (43.8)

1.00

0.57–1.74

0.993

 Discriminations

250 (45.3)

39 (34.2)

1.38

0.47–2.58

0.315

234 (39.9)

38 (31.4)

0.77

0.43–1.38

0.386

 Unexpected negative effects

228 (41.4)

38 (33.0)

1.02

0.54–1.93

0.963

192 (32.6)

33 (27.5)

0.49

0.26–0.90

0.022

 Cloned human beings

203 (37.0)

35 (30.4)

0.87

0.46–1.66

0.682

191 (32.5)

24 (20.2)

2.27

1.16–4.46

0.017

 Company or government bodies use genome information

267 (48.8)

33 (29.7)

1.35

0.77–2.36

0.299

251 (42.7)

30 (25.0)

1.71

0.98–3.00

0.060